Przejdź do treści
Radio Logo
PodcastyWiadomościBeyond Biotech - the podcast from Labiotech

Beyond Biotech - the podcast from Labiotech

Labiotech
Najnowszy odcinek

223 odcinków

  • Beyond Biotech - the podcast from Labiotech

    Inside Arbor’s CNS pipeline and next-generation gene editing

    13.11.2026 | 32 min.
    Gene editing has spent the last decade proving what's possible in the lab. The next decade is about proving it can reach the patients who need it most, from ultra-rare liver diseases to conditions like ALS, where no truly effective treatments exist today. 
    Arbor Biotechnologies is one of the companies pushing that frontier, built on a diverse toolbox of editing technologies that goes beyond the limitations of first-generation CRISPR tools. Its lead clinical program, ABO-101, targets PH1, and last October the company struck a partnership with Chiesi Group worth up to two billion dollars in milestones, with European regulators granting the program orphan drug designation just this summer. 
    Arbor is also building out a CNS pipeline focused initially on ALS. Here to talk through the science, the strategy, and what's next is Devyn Smith, CEO of Arbor Biotechnologies.
    01:36 – Meet Devyn Smith
    07:48 – Arbor's toolbox approach versus single-editor CRISPR companies
    12:16 – What PH1 is and how ABO-101 works
    15:19 – Inside the Chiesi partnership for ABO-101
    20:14 – Why ALS anchors Arbor's CNS pipeline
    26:48 – Arbor's three-year outlook and long-term vision
    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 
    Stay updated by subscribing to our newsletter
    To dive deeper into the topic: 
    What’s on the horizon for gene editing-based therapies?
    CRISPR technology’s next wave: Ten companies to watch in 2025 
    Beyond CRISPR: What CAST could bring to genome editing
  • Beyond Biotech - the podcast from Labiotech

    How to turn a BIO-Europe meeting into a lasting partnership

    06.11.2026 | 31 min.
    Partnering season is here. As the biopharma community heads to BIO-Europe and the busy end-of-year conference calendar, the question isn’t just who you meet, but how you make those meetings count. In this special episode of Beyond Biotech, we’re talking about the small details that make a big difference at global conferences.
    Joining me is Shashi Koduru, Senior Director of Business Development at Vector BioMed. Shashi shares how he plans his on-site schedule, finds the right partners, and makes short meetings productive. We also talk about follow-up, sharing materials after the event, and turning a first conversation into a lasting partnership.
    01:15 Meet Shashi Koduru
    05:13 Vector BioMed’s mission for affordable lentiviral vectors
    09:36 Cutting through the noise with early conference prep
    19:04 Making the most of a 30-minute partnering meeting
    22:46 How a chance BIO encounter became a client
    25:24 Following up and maintaining momentum after the event
    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 
    Stay updated by subscribing to our newsletter
    To dive deeper into the topic: 
    Episode 188: How to optimize your biotech company for partnering, licensing, and business success
    The ABC of biotech partnerships
    Nine tips to succeed in pharma-biotech partnerships
  • Beyond Biotech - the podcast from Labiotech

    Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)

    30.10.2026 | 34 min.
    Welcome to a special three-part series called 'The Metabolic Moment'.
    In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.
    So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.
    In part three of our series and ahead of Diabetes Awareness Month, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes, the realities of making gene therapies at scale, and where a potential one-time treatment could fit alongside GLP-1s.
    02:21 Meet Ryan Confer and Genprex
    09:49 What gene therapy can offer patients that GLP-1s cannot
    12:36 How GPX-002 works and the type 2 diabetes data presented at ASGCT
    17:22 Working with a CDMO to manufacture an AAV gene therapy at scale
    20:07 Standing out from GLP-1s and stem cell approaches in diabetes
    27:59 Diabetes Awareness Month and the prospect of a functional cure
    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 
    Stay updated by subscribing to our newsletter
    To dive deeper into the topic: 
    The Metabolic Moment: 3 big bets to watch in metabolic disease
    Beyond GLP-1s: is there a new wave of metabolic disease treatments?
    The future of diabetes treatment: Is a cure possible?
  • Beyond Biotech - the podcast from Labiotech

    GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)

    23.10.2026 | 28 min.
    Welcome to a special three-part series called 'The Metabolic Moment'.
    In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.
    So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.
    In part two of our series,  I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants.
    02:24 Meet Paul Little
    05:08 What GLP-1s leave unsolved, from muscle loss to weight rebound
    10:29 How ATR-258 tunes beta-2 signalling to mimic exercise
    16:11 Avoiding the cardiovascular side effects of older beta-2 agonists
    19:03 What the new muscle power and body composition data mean
    22:03 Phase 2 options, oral advantages and the path to partnering
    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 
    Stay updated by subscribing to our newsletter
    To dive deeper into the topic: 
    The Metabolic Moment: 3 big bets to watch in metabolic disease
    Beyond Ozempic: the GLP-1 landscape in 2026 
    What can GLP-1s do beside treat diabetes and obesity?
  • Beyond Biotech - the podcast from Labiotech

    The next big shake-up in the GLP-1 market? (Part 1 of 3)

    16.10.2026 | 36 min.
    Welcome to a special three-part series called 'The Metabolic Moment'.
    In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure.
    So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment.
    In part one of our series,  I’m joined by Valeriia Simanovskaia, founder and CEO of BioBrokers, an independent capital markets and strategic advisory firm for life sciences. Trained at Harvard Medical School and based in Paris, Valeriia tracks where the money in biotech is flowing.
    02:15 Meet Valeriia and BioBrokers
    09:07 Discontinuation rates and what they mean for GLP-1 sales
    12:39 Generic semaglutide arrives in India and Canada
    16:28 Why oral GLP-1s may become a separate market segment
    22:15 Amgen’s MariTide and the case for monthly dosing
    32:00 Why weight maintenance is the next competitive frontier
    Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 
    Stay updated by subscribing to our newsletter
    To dive deeper into the topic: 
    The Metabolic Moment: 3 big bets to watch in metabolic disease
    Beyond Ozempic: the GLP-1 landscape in 2026 
    Nine biotech companies that could revolutionize obesity treatments
Więcej Wiadomości podcastów
O Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Strona internetowa podcastu

Słuchaj Beyond Biotech - the podcast from Labiotech, Gość Radia ZET i wielu innych podcastów z całego świata dzięki aplikacji radio.pl

Uzyskaj bezpłatną aplikację radio.pl

  • Stacje i podcasty do zakładek
  • Strumieniuj przez Wi-Fi lub Bluetooth
  • Obsługuje Carplay & Android Auto
  • Jeszcze więcej funkcjonalności